Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial

Why It Matters

Fenebrutinib could break Ocrevus’s monopoly in PPMS, offering an oral option that targets both inflammation and neurodegeneration, potentially expanding treatment choices for a disease with limited therapies.

Key Takeaways

• Fenebrutinib non‑inferior to Ocrevus in disability progression
• 12% risk reduction in 12‑week confirmed disability progression
• 26% lower nine‑hole peg test worsening versus Ocrevus
• Safety similar; liver enzymes mildly elevated, no severe injury
• First BTK inhibitor poised for MS approval, addressing unmet need

Pulse Analysis

Primary progressive multiple sclerosis (PPMS) accounts for roughly 15 % of the global MS population and remains one of the most therapeutically underserved neuro‑degenerative disorders. Unlike relapsing‑remitting forms, PPMS is characterized by a steady accumulation of disability without clear inflammatory relapses, limiting the effectiveness of conventional disease‑modifying drugs. Ocrevus (ocrelizumab) is currently the sole FDA‑approved agent for PPMS, delivering modest benefits through B‑cell depletion but requiring intravenous infusion. The emergence of an oral, central‑nervous‑system‑penetrant Bruton’s tyrosine kinase (BTK) inhibitor therefore represents a potential paradigm shift, promising easier administration and broader mechanistic coverage of both immune and microglial pathways.

The Phase III FENtrepid trial enrolled patients with early‑stage PPMS and compared fenebrutinib against Ocrevus over a minimum of 120 weeks. The primary endpoint—time to 12‑week confirmed disability progression—showed a 12 % relative risk reduction for fenebrutinib, meeting the pre‑specified non‑inferiority margin and indicating comparable disease‑slowing capacity. Notably, the drug delivered a 26 % reduction in nine‑hole peg test deterioration, highlighting superior preservation of upper‑limb function, a critical determinant of daily independence. Safety signals were largely aligned with the comparator, aside from transient liver enzyme elevations that did not progress to Hy’s Law.

Roche plans to bundle fenebrutinib data from both the PPMS FENtrepid study and the relapsing‑MS FENhance trials for a dual‑indication regulatory filing later this year. If approved, fenebrutinib would become the first BTK inhibitor sanctioned for multiple sclerosis, expanding the oral therapeutic arsenal and challenging Ocrevus’s market dominance. Competitors such as Novartis’ remibrutinib and Sanofi’s tolebrutinib face safety hurdles, giving Roche a timing advantage. Payers and clinicians will likely weigh the modest efficacy gains against the need for liver monitoring, but the oral route and broader mechanism could drive rapid adoption.